Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro

Archive ouverte

Fénéant, Lucie | Ghosn, Jade | Fouquet, Baptiste | Helle, Francois | Belouzard, Sandrine | Vausselin, Thibaut | Séron, Karin | Delfraissy, François | Dubuisson, Jean | Misrahi, Micheline | Cocquerel, Laurence

Edité par CCSD ; Public Library of Science -

International audience. The clinical course of Hepatitis C Virus (HCV) infection is highly variable between infected individual hosts: up to 80% of acutely HCV infected patients develop a chronic infection while 20% clear infection spontaneously. Spontaneous clearance of HCV infection can be predicted by several factors, including symptomatic acute infection, favorable IFNL3 polymorphisms and gender. In our study, we explored the possibility that variants in HCV cell entry factors might be involved in resistance to HCV infection. In a same case patient highly exposed but not infected by HCV, we previously identified one mutation in claudin-6 (CLDN6) and a rare variant in occludin (OCLN), two tight junction proteins involved in HCV entry into hepatocytes. Here, we conducted an extensive functional study to characterize the ability of these two natural variants to prevent HCV entry. We used lentiviral vectors to express Wildtype or mutated CLDN6 and OCLN in different cell lines and primary human hepatocytes. HCV infection was then investigated using cell culture produced HCV particles (HCVcc) as well as HCV pseudoparticles (HCVpp) expressing envelope proteins from different genotypes. Our results show that variants of CLDN6 and OCLN expressed separately or in combination did not affect HCV infection nor cell-to-cell transmission. Hence, our study highlights the complexity of HCV resistance mechanisms supporting the fact that this process probably not primarily involves HCV entry factors and that other unknown host factors may be implicated.

Suggestions

Du même auteur

Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus

Archive ouverte | Vausselin, Thibaut | CCSD

International audience. Aminoquinolines and piperazines, linked or not, have been used successfully to treat malaria, and some molecules of this family also exhibit antiviral properties. Here we tested several deriv...

The antimalarial ferroquine is an inhibitor of hepatitis C virus

Archive ouverte | Vausselin, Thibaut | CCSD

Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report ...

New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore Monensin A

Archive ouverte | Fénéant, Lucie | CCSD

International audience. In our study, we characterized the effect of monensin, an ionophore that is known to raise the intracellular pH, on the hepatitis C virus (HCV) life cycle. We showed that monensin inhibits HC...

Chargement des enrichissements...